Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
Randomized clinical trials have proven the efficacy and safety of Food and Drug Administration (FDA) approved anti-obesity medications (AOMs) for long-term use. It is unclear whether these outcomes can be replicated in real-world clinical practice where clinical complexities arise. The aim of this study was to evaluate the effectiveness and side effects of these medications in real-world multidisciplinary clinical practice settings. We reviewed the electronic medical records (EMR) of patients with obesity who were prescribed an FDA-approved AOM for long-term use in academic and community multidisciplinary weight loss programs between January 2016 and January 2020. We assessed percentage total body weight loss (%TBWL), metabolic outcomes, and side effect profile up to 24 months after AOM initiation. The full cohort consisted of 304 patients (76% women, 95.2% White, median age of 50 years old [IQR, 39–58]). The median follow-up time was 9.1 months [IQR, 4.2–14.1] with a median number of 3 visits [IQR, 2–4]. The most prescribed medication was phentermine/topiramate extended-release (ER) (51%), followed by liraglutide (26.3%), bupropion/naltrexone sustained-release (SR) (16.5%), and lorcaserin (6.2%). %TBWL was 5.0%, 6.8%, 9.3%, 10.3%, and 10.5% at 3, 6, 12, 18, and 24 months. 60.2% of the entire cohort achieved at least 5% TBWL. Overall, phentermine/topiramate-ER had the most robust weight loss response during follow-up, with the highest %TBWL at 12 months of 12.0%. Adverse events were reported in 22.4% of patients. Only 9% of patients discontinued the medication due to side effects. AOMs resulted in significant long-term weight loss, that was comparable to outcomes previously reported in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, patients with type 2 diabetes were also represented in many studies51,53,54,56,57,59,62,63,65,68–71.”
From Incretin-based therapies for the treatment of obesity-related diseases (2024) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Prevalence of Obesity Among Adults and Youth: United States, 2015-2016.
Hales, C. M., Carroll, M. D., Fryar, C. D., & Ogden, C. L. (2017) · PubMed · Cited by 3,884
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Mechanisms, Pathophysiology, and Management of Obesity
Heymsfield, S. B., & Wadden, T. A. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1514009 · Cited by 1,867 · cited 1×
“While behavioral modification based on increased exercise and caloric restriction remains the cornerstone of weight management, the success rates and long-term durability of this intervention are inconsistent [5, 6].”
BackgroundCaregiving for Older Adults with Obesity in the United States
Ankuda, C. K., Harris, J., Ornstein, K., Levine, D. A., Langa, K. M., & Kelley, A. S. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14918 · Cited by 1,684
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064 · cited 1×
“4% with phentermine/topiramate-ER versus 11% in our study [12, 19], and 6.”
BackgroundGreenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60888-4 · Cited by 1,036
Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911
Research works printed but not linked: 1
- Lewis KH, Fischer H, Ard J, Barton L, Bessesen DH, Daley MF, et al. Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort. Obesity. 2019;27:591–602. · DOI · Paper page
Cited by
Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity
Ghusn, W., De la Rosa, A., Sacoto, D., Cifuentes, L., Campos, A., Feris, F., Hurtado, M. D., & Acosta, A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.31982 · Cited by 238
Self-citationKong, X., Liu, C., Zhang, Z., Cheng, M., Mei, Z., Li, X., Liu, P., Diao, L., Ma, Y., Jiang, P., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkad926 · Cited by 205
Narrative Review of Topiramate: Clinical Uses and Pharmacological Considerations
Pearl, N. Z., Babin, C. P., Catalano, N. T., Blake, J. C., Ahmadzadeh, S., Shekoohi, S., & Kaye, A. D. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02586-y · Cited by 79
Effectiveness and safety of drugs for obesity
Henderson Lewis, K., Sloan, C. E., Bessesen, D. H., & Arterburn, D. (2024) · BMJ · doi:10.1136/bmj-2022-072686 · Cited by 66
A narrative review of approved and emerging anti-obesity medications
Beshir, S. A., Elnour, A. A., Soorya, A., Mohamed, A. P., Goh, S. S. L., Hussain, N., Haddad, A. H. I. A., Hussain, F., Khidir, I. Y., & Abdelnassir, Z. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.101757 · Cited by 64
“A multisite study review of patients’ medical records has recommended monitoring AOM for adverse events (Pearl NZ et al., 2023; Valladales-Restrepo LF et al., 2023; Calderon G et al., 2022).”
Metadata
- Authors
- Calderon, G., Gonzalez-Izundegui, D., Shan, K. L., Garcia-Valencia, O. A., Cifuentes, L., Campos, A., Collazo-Clavell, M. L., Shah, M., Hurley, D. L., Abu Lebdeh, H. S., Sharma, M., Schmitz, K., Clark, M. M., Grothe, K., Mundi, M. S., Camilleri, M., Abu Dayyeh, B. K., Hurtado Andrade, M. D., Mokadem, M. A., & Acosta, A.
- Affiliations
- University of Iowa (US)
- Mayo Clinic (US)
- Corresponding author
- Mokadem, Mohamad A.
- Acosta, Andres
- ORCID
- Venue
- International Journal of Obesity
- Published
- 2021-11-22
- Volume
- 46
- Issue
- 3
- Pages
- 555-563
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- PMC
- PMC8881310
- OpenAlex
- W3217240228
- Semantic Scholar
- 4d8de3953ee85f85ede0c4cc8d1eb4f2f3793ed7
- Cited by
- 52
- References
- 37
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 17 · 2023: 10 · 2022: 6
- FWCI
- 4.78
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- International Journal of Obesity (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK114460)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- anti-obesity drugs, obesity, weight loss, liraglutide, lorcaserin, real-world effectiveness, adverse events, drug discontinuation, metabolic outcomes
- MeSH terms
- Topiramate, Adult, Female, Humans, Male, Middle Aged, Obesity, Phentermine, Weight Loss, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience. https://app.cochat.ai/papers/10.1038/s41366-021-01019-6
- The paper
- Calderon, G., Gonzalez-Izundegui, D., Shan, K. L., Garcia-Valencia, O. A., Cifuentes, L., Campos, A., Collazo-Clavell, M. L., Shah, M., Hurley, D. L., Abu Lebdeh, H. S., Sharma, M., Schmitz, K., Clark, M. M., Grothe, K., Mundi, M. S., Camilleri, M., Abu Dayyeh, B. K., Hurtado Andrade, M. D., Mokadem, M. A., & Acosta, A. (2022). Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience. International Journal of Obesity. https://doi.org/10.1038/s41366-021-01019-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.